Imperial College London

Dr Mark P. Lythgoe

Faculty of MedicineDepartment of Surgery & Cancer

Research Postgraduate







Institute of Reproductive and Developmental BiologyHammersmith Campus





Dr Mark P. Lythgoe is an Academic Clinical Fellow in Medical Oncology and Pharmacist.  He is currently undertaking a PhD (primary supervisor Dr Jonathan Krell) exploring the cancer microbiome and live oral biotherapeutics as novel anti-cancer agents. Presently he oversees (principal investigator Dr Krell) the Imperial sponsored MICROBIOME trial (NCT03934827) with industry partner 4D Pharma exploring use of a live oral biotherapeutics (MRx0518) in patients with solid tumours awaiting surgical removal of the tumour. 

After studying Pharmacy at Aston University, Mark went on to graduate with a duel distinction in Medicine from Kings College London.  After completion of junior doctor posts in west London, he is now undertaking specialist academic training in Medical Oncology. He has also undertaken an academic clinical fellowship placement with Dr Rohini Sharma, exploring prognostic indices in high grade neuroendocrine tumours and PET imaging in a range of solid cancers, utilizing novel radionuclides to predict therapy responses. 

He has a range of academic interests including translational clinical trial development, cancer microbiome modulation as a therapeutic strategy, healthcare policy, improving clinical trial access and meta-research. He has also been a member of the Joint Formulary Committee for the British National Formulary (BNF) for 8 years.

He received an American Society of Cancer Merit Award in 2021 and has authored papers in the JAMA Oncology, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, and Trends in Pharmacological Sciences.  He also reviews manuscripts for several journals including Cancer, Scientific Reports, Trends in Pharmacological Sciences and European Journal of Cancer. 



Khanna S, Sarwar N, Caldwell R, et al., 2024, Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023)., Journal of Clinical Oncology, Vol:42, ISSN:0732-183X, Pages:432-432

Benjamin DJ, Lythgoe MP, Kalebasty AR, 2024, Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020., Jco Oncol Pract

Harris BHL, Mccabe C, Shafique H, et al., 2024, Diversity of thought: public perceptions of genetic testing across ethnic groups in the UK, Journal of Human Genetics, Vol:69, ISSN:1434-5161, Pages:19-25

Jenei K, Lythgoe MP, Vokinger KN, 2024, Shortages of essential cancer medicines: who is responsible and what are the possible solutions?, Lancet Oncol, Vol:25, Pages:23-26

Julve M, Kennedy O, Frampton AE, et al., 2023, Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)., J Clin Pathol, Vol:77, Pages:1-7

More Publications